Evidence map›Paper›PMID 20625819›Full record

ArticleBreast cancer research and treatment2011

Native MAG-1 antibody almost destroys human breast cancer xenografts.

William G North, Roy H L Pang, Guohong Gao, Vincent A Memoli, Bernard F Cole

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

William G NorthDepartments of Physiology and Pathology, Dartmouth Medical School, Lebanon, NH 03756, USA. william.g.north@dartmouth.edu
Roy H L Pang
Guohong Gao
Vincent A Memoli
Bernard F Cole
Dartmouth College · USUniversity of Vermont · USWoomera Therapeutics · US

Funding

NMDA receptors in the diagnosis and treatment of breast cancerR21CA135428 · NCI · DARTMOUTH COLLEGE · PI NORTH, WILLIAM G · 2010 to 2011
$334k
MAG-1 Targeting of GRSA on Breast CancerR43CA119483 · NCI · WOOMERA THERAPEUTICS, INC. · PI PANG, ROY H.L. · 2006 to 2006
$100k
NCI NIH HHS 1R43CA119483-01NCI NIH HHS R21 CA135428NCI NIH HHS R43 CA119483
6 · The paper itself

Abstract

A native form of mouse monoclonal IgG1 antibody called MAG-1, which recognizes an epitope on provasopressin, has been found to shrink and produce extensive necrosis of human breast tumor xenografts in nu/nu mice. We examined the ability of (90)Yttrium-labeled and native MAG-1 to affect the growth in nu/nu mice of cancer xenografts that were estrogen-responsive (from MCF-7 cells) and triple-negative (from MDA-MB231 cells). The growth rates of treated cells were compared to those receiving saline vehicle and those receiving (90)Yttrium-labeled and native forms of the ubiquitous antibody, MOPC21. Short-term treatments (4 doses over 6 days) not only with (90)Yttrium-MAG-1 but also native MAG-1 produced large reductions in size of rapidly growing tumors of both types, while both (90)Yttrium- MOPC21 and native MOPC21 had no effect. Native and (90)Yttrium-MAG-1 effects were similar, and arrested tumors recommenced growing soon after treatments stopped. Increasing native MAG-1 treatment to single dosing for 16 consecutive days shrank tumors of both types with no regrowth apparent over a 20-day post-treatment period of observation. Pathological examination of such tumors revealed they had undergone very extensive (>66%) necrosis.

Indexed as

AnimalsAntibodies, MonoclonalBreast NeoplasmsCell Line, TumorFemaleHumansMaleMiceMice, NudeVasopressinsXenograft Model Antitumor AssaysYttriumAntibodies, MonoclonalMOPC21 monoclonal antibodyVasopressinsYttrium

Identifiers

PMID20625819
PMCPMC4521588
OpenAlexW1995744615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.